Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

AIDS drug helps to keep HBV at bay during chemotherapy for breast cancer

18.03.2004


Researchers in Hong Kong have discovered a way to help prevent the reactivation of the hepatitis B virus in women who are being treated with chemotherapy for breast cancer.



Dr Winnie Yeo told the 4th European Breast Cancer Conference in Hamburg: "In several developing countries, as many as twelve per cent of breast cancer patients carry the hepatitis B virus. These patients are at risk of developing HBV reactivation during chemotherapy, which is a well-known complication resulting in varying degrees of liver damage that may lead to death."*

Chemotherapy suppresses the immune system and therefore allows the virus to replicate. Once chemotherapy stops, the immune system recovers and attempts to clear the virus and this causes the biochemical flare-up of hepatitis.


However, Dr Yeo has found that the anti-viral drug lamivudine can reduce the risk of HBV reactivation during and after chemotherapy. Lamivudine was initially used for treating HIV infection in AIDS patients and now is used frequently for treating HBV infection.

Dr Yeo, an associate professor in the Department of Clinical Oncology at the Chinese University of Hong Kong, treated 27 HBV-carrying breast cancer patients with lamivudine before, during and up to eight weeks after chemotherapy. She compared the results with a control group of 41 consecutive patients who had had chemotherapy without lamivudine and compared the incidence of HBV reactivation, hepatitis, severe hepatitis and any consequent disruption to the chemotherapeutic regime.

"We found that lamivudine significantly reduced the incidence of HBV reactivation, and that the incidence of hepatitis from all causes was reduced," said Dr Yeo.

Only two patients out of the 27 receiving lamivudine suffered HBV reactivation compared with 17 out of 41 in the control group (seven per cent versus 41 per cent); three patients in the study group suffered from hepatitis and two from severe hepatitis (eleven and seven per cent) compared with 27 patients in the control group who developed hepatitis and six who developed severe hepatitis (66 and 15 per cent). Chemotherapy was disrupted in seven (26 per cent) of the study group and in 21 (51 per cent) of the control group.

Patients in both groups were similar, although more patients were being treated with anthracyclines in the lamivudine group (26 out of 27 patients) than in the control group (23 out of 41 patients).

Dr Yeo said: "These results show very clearly that prophylactic lamivudine significantly reduces the incidence of both HBV reactivation and hepatitis. Therefore I propose that breast cancer patients who are hepatitis B carriers should have anti-viral treatment before the start of chemotherapy."

Emma Mason | EurekAlert!
Further information:
http://www.fecs.be/

More articles from Health and Medicine:

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

nachricht What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>